Fisher Asset Management LLC Lowers Position in Prestige Consumer Healthcare Inc. $PBH

Fisher Asset Management LLC trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 305,626 shares of the company’s stock after selling 22,434 shares during the quarter. Fisher Asset Management LLC owned about 0.62% of Prestige Consumer Healthcare worth $24,404,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $41,848,000. Kayne Anderson Rudnick Investment Management LLC lifted its position in Prestige Consumer Healthcare by 45.3% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock valued at $135,903,000 after purchasing an additional 493,199 shares during the last quarter. Invesco Ltd. grew its stake in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares in the last quarter. Tributary Capital Management LLC purchased a new position in Prestige Consumer Healthcare in the 2nd quarter worth approximately $11,773,000. Finally, Edgestream Partners L.P. bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth $10,821,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.2%

Shares of PBH stock opened at $59.80 on Wednesday. The business has a 50-day moving average of $61.16 and a 200 day moving average of $70.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The stock has a market capitalization of $2.88 billion, a PE ratio of 14.04, a P/E/G ratio of 1.93 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The business had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Oppenheimer dropped their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Finally, Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is owned by corporate insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.